Samsung Biologics announced the launch of an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide Group, a leading global contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients (APIs).
Aptar Pharma has launched a collaborative system-level framework designed to support the development of injectable drug delivery systems. The framework will enable pharmaceutical partners to access integrated data packages combining system-level testing and performance data for injectable therapies.
Brenntag has entered into a new strategic partnership with Evonik Rexim for the distribution of GMP-compliant amino acids in the European pharmaceutical and biopharmaceutical markets. The agreement covers most of Europe, including the DACH region, the United Kingdom, France, Benelux, Scandinavia, CEE, Israel, Turkey and more.
According to a global women’s health investment report from W Group, disclosed equity secured by companies in the space last year was up 41% compared to 2024. The report tracked more than 500 funding stories and around 164 disclosed rounds of equity across clinical and consumer categories.
The UK government has committed to maintaining its existing intellectual property (IP) framework for pharmaceuticals as part of a new trade deal with Switzerland. The agreement locks in place IP protections in the UK and Switzerland, meaning neither country will be able to amend periods of exclusivity for drugs or usher in generics in a specific indication earlier than planned.
